Semaglutide's evolution from weekly injections to an SNAC-enabled tablet preserved its metabolic and cardiovascular efficacy. Large injectable CVOTs have demonstrated robust cardioprotection, and the SOUL trial now shows a 14% reduction in major adverse cardiovascular events with the oral formulation.These data confirm formulation-independent benefit, positioning oral semaglutide as the only cardioprotective, non-injectable, GLP-1RA for high-risk type 2 diabetes.